> ## Content Index > Fetch the complete content index at: https://www.legalexaminer.com/llms.txt > Use this file to discover other available public pages before exploring further. # Antitrust Lawsuits Show Why Some Generic Drugs are so Expensive as Claims Deadline Nears - URL: https://www.legalexaminer.com/lestaffer/legal/antitrust-lawsuits-show-why-some-generic-drugs-are-so-expensive-as-claims-deadline-nears/ - Published: 2026-08-21T14:25:20.000Z - Updated: 2026-08-21T14:25:20.000Z - Description: Generic drugs are supposed to be affordable, but antitrust lawsuits allege pharmaceutical companies secretly fixed prices for over a decade, resulting in $850 million in settlements so far. Affected Americans can file a claim through the generic drug price-fixing website by November 9, 2026. - Author: Legal Examiner Staffer - Tags: Legal, Health Generic drugs make up about 90% of all prescriptions filled in the U.S. because they’re supposed to be the cheap alternative to brand-name medications. But for a over a decade, some of the largest generic drug manufacturers allegedly worked together in secret to keep prices artificially high instead of competing for lower ones. And it’s cost consumers, employers, and taxpayer-funded health programs billions of dollars. The allegations are the subject of a sprawling federal lawsuit based on [antitrust laws](https://www.justice.gov/atr/antitrust-laws-and-you?ref=legalexaminer.com) that prohibit companies from creating anticompetitive markets. In 2016, the generic pharmaceuticals pricing antitrust MDL was created, and it’s progressed alongside related lawsuits from a coalition of state attorneys general. States say the generic drug price-fixing scheme touched a range of daily and lifechanging medicines; cholesterol pills, seizure medication, antibiotic ointment, and even cancer treatments are at the center of the litigation. So far, numerous settlements have been reached with drug companies totaling over $850 million, including a landmark $450 million agreement with Swiss drugmaker Sandoz in early August. There’s also a separate, newer state lawsuit involving Novartis, the former parent company of Sandoz. Novartis is accused of fixing prices on 31 more medications and of trying to shield itself from liability by spinning off Sandoz as an independent company. Throughout the litigation, extensive evidence has shown that shady practices likely caused or contributed to why some generic drugs are so expensive. ## How Did Drug Companies Fix Prices? The alleged drug price-fixing scheme dates back to at least 2012\. According to state investigators, generic medication company executives divided up which company would offer the lowest price to a given pharmacy or distributor. Following that, competitors would submit intentionally higher “cover bids” to make the process look competitive. Investigators in the state-led drug price-fixing litigation built their case on millions of texts, emails, and phone records, and say some of the coordination happened at informal industry gatherings. The evidence is claimed to show the scheme was planned during social gatherings and events, like golf outings, [girls’ nights out](https://www.pbs.org/newshour/health/generic-drug-companies-fixed-prices-swanky-dinners-lawsuit-says?ref=legalexaminer.com), and dinners with pharmaceutical executives and salespeople. Because generic drugs are supposed to compete on price once a brand name drug’s patent expires, this kind of coordination defeats the purpose of the generic market. And the effects showed up in what consumers, insurers, and programs like Medicare and Medicaid paid at the counter. By Spring 2021, the antitrust division at the [Department of Justice had charged four senior executives](https://www.justice.gov/atr/division-operations/division-update-spring-2021/generic-drugs-investigation-targets-anticompetitive-schemes?ref=legalexaminer.com) and seven generic pharmaceutical companies for conspiring to fix drug prices. Three executives pleaded guilty, and two former Heritage Pharmaceuticals executives became cooperating witnesses early in the investigation. ## What Generic Drugs Were Price-Fixed? State lawsuits name more than 100 generic drugs across multiple complaints, including widely used medications such as: - Pravastatin (cholesterol) - Carbamazepine (seizure disorders) - Tobramycin (antibiotic) - Novartis diabetes, epilepsy, and psychosis medications - Clobetasol, clotrimazole, desonide, and fluocinonide (dermatology/ topical treatments) One state attorney general’s office said the alleged conspiracies to create an anticompetitive generics market caused [consumers to pay more than 10 times as much for some medications](https://www.atg.wa.gov/news/news-releases/ag-ferguson-bipartisan-coalition-win-49-million-and-counting-over-generic-drugs?ref=legalexaminer.com). There’s precedent for numbers that stark: a similar pharmaceutical price-fixing case decades ago led to consumers paying as much as 3200% more for an anti-anxiety medication. ## Sandoz’s $450 Million Price-Fixing Settlement A [$450 million deal with Sandoz to settle drug price-fixing](https://www.doj.nh.gov/news-and-media/400-million-settlement-principle-sandoz-generic-drug-price-fixing-litigation?ref=legalexaminer.com) was announced on August 3, 2026\. Starting in 2027, Sandoz and its subsidiary Fougera Pharmaceuticals will pay $400 million over seven years, plus $50 million to states that had already settled earlier claims. The nearly half billion-dollar settlement resolves claims brought by 43 states and territories. While substantial, Sandoz didn’t admit any wrongdoing, which is standard for civil cases of this kind. ## New Antitrust Lawsuit Against Novartis Filed The Sandoz settlement doesn’t end the case. In February 2026, a coalition of 42 states and territories sued Novartis, the former parent company of Sandoz, along with its subsidiaries Sandoz Group AG and Sandoz AG. States claim they conspired in a separate scheme to fix prices, allocate markets, and rig bids on 31 more generic drugs. The complaint also makes a striking allegation – that [Novartis fraudulently drained assets from Sandoz](https://www.njoag.gov/acting-ag-davenport-files-multistate-complaint-against-novartis-and-sandoz-alleging-prescription-drug-price-fixing/?ref=legalexaminer.com) and spun the company off as independent, specifically to dodge liability for price fixing. The first trial related to the Novartis case is expected in late 2026, in Hartford, Connecticut. ## How to Check If You’re Owed Money for Generic Drug Price-Fixing There are two separate compensation programs for people who were affected by the anticompetitive generics scheme: 1. **Federal end-payer class action – deadline November 9, 2026**: If you or your health plan paid for a covered generic drug between May 1, 2009, and December 31, 2019, you can file a claim now through the [Generic Pharmaceuticals Antitrust MDL website](https://genericdrugsendpayersettlement.com/?ref=legalexaminer.com). This covers the Sandoz, Sun/Taro, Apotex, and Heritage settlements. Filing a claim requires consumers to list the drugs purchased, along with proof of payment, such as a receipt or pharmacy record. No attorney or claims-recovery firm is needed. 2. **State attorneys general restitution fund – registration now open**: A coalition of state AGs has settled with several manufacturers, including Glenmark, Lannett, Bausch, Apotex, and Heritage for a total of $96 million. However, the program hasn’t opened its claim form yet as it’s still gathering settlement funds. Consumers can register for updates at the official [AG Generic Drugs Settlement website](https://www.aggenericdrugs.com/?ref=legalexaminer.com) or call 1-866-290-0182. ## How Generic Drug Price-Fixing Lawsuits Affect Americans The decades-long generic pharmaceuticals antitrust cases show the system depends on manufacturers competing once a drug’s patent is over. For years, some of the largest drug companies in the industry allegedly agreed not to compete, causing Americans to pay more for their medications instead of a fair price. With the November 9, 2026, deadline approaching and a second case progressing against Novartis, affected consumers have a concrete, time-limited way to get some of that money back.